About: Cardiac Hypertrophy Pathway

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Cardiac Hypertrophy Pathway Goto Sponge NotDistinct Permalink

An Entity of Type : owl:Class, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	Class
rdfs:label	Cardiac Hypertrophy Pathway
rdfs:subClassOf	Disease Pathway
Semantic_Type	Functional Concept
Preferred_Name	Cardiac Hypertrophy Pathway
UMLS_CUI	C1516292
BioCarta_ID	h_cardiacegfPathway
ALT_DEFINITION	One of responses to increased blood pressure is cardiac hypertrophy through increased size of ventricular myocardial cells leading to increased thickness of the ventricular walls. Cardiac hypertrophy allows the heart to handle the increased stress caused by elevated blood pressure but is also a risk factor associated with heart disease. Cardiac hypertrophy results from cross-talk between G-protein coupled receptor signaling and the EGF receptor pathway. Several GPCR ligands are known to stimulate cardiac hypertrophy, including factors that regulate blood pressure such as angiotensin II and endothelin-1. These factors stimulate phospholipase C through Gq activation, and the production of 1P3 and diacylglycerol second messengers. PKC-delta is activated by DAG and interacts with the metalloproteinase ADAM12. ADAM12 cleaves the membrane-bound HB-EGF to release soluble EGF ligand that activates EGF receptor in myocardial cells. EGF receptor activation downstream through small G proteins and the MAP kinase pathway ultimately leads to cardiac hypertrophy. Signals by GPCR ligands such as angiotensin II result in transcriptional translation of immediate early genes like fos and other genes involved in long-term remodeling of heart tissue and the physiological response to stress in the heart such as the atrial natriuretic factor. Factors such as the AKT kinase, reactive oxygen species (ROS) and NE-kB also are involved in signaling that leads to hypertrophy, although their role is not yet clear. Blocking this pathway at various steps may prevent heart disease through the prevention of cardiac hypertrophy, but may also have other consequences.BIOCARTA
Legacy_Concept_Name	Cardiac_Hypertrophy_Pathway
FULL_SYN	Role of EGF Receptor Transactivation by GPCRs in Cardiac HypertrophyPTBIOCARTA Cardiac Hypertrophy PathwayPTNCI
code	C39011
is someValuesFrom of	nodeID://b641892 nodeID://b642154 nodeID://b642164 nodeID://b646070 nodeID://b646100 nodeID://b667010 nodeID://b668316 nodeID://b668556 nodeID://b668618 nodeID://b670243 nodeID://b670428 nodeID://b670460 nodeID://b672576 nodeID://b672646 nodeID://b678881 nodeID://b684641 nodeID://b684733 nodeID://b691390 nodeID://b695029 nodeID://b699859 nodeID://b700700 nodeID://b705173 nodeID://b706787 nodeID://b724381 nodeID://b725661 nodeID://b726293

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 83 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software